Skip to main content
. 2024 Mar 20;28(7):e18213. doi: 10.1111/jcmm.18213

FIGURE 2.

FIGURE 2

In order to verify the expression of YARS1 in bladder cancer and assess its prognostic significance, tissue microarray analysis was performed. (A, B) The level of YARS1 expression was examined in both bladder cancer and normal tissues using immunohistochemical staining. (C) A comparison was made between YARS1 expression in unmatched bladder cancer and normal bladder tissues. (D) YARS1 expression was evaluated in paired bladder cancer tissues. (E) Prognostic value of YARS1 expression was assessed by analysing the survival time difference between patients in the high‐expression and low‐expression groups. (F) Survival/death ratio of patients in the high‐expression group and low‐expression group of YARS1. (G) Distribution patterns of bladder cancer patients based on stage, grade and other clinical factors. (H) YARS1 expression was subjected to Kaplan–Meier survival analysis. (I, J) Predictive ability of YARS1 expression for the 1‐, 3‐ and 5‐year prognosis of bladder cancer patients was analysed. **p < .01, ***p < .001.